SCHEMBL17314867

SCHEMBL17314867

Cc1cccc(-c2nc3nc(Cl)nc(N[C@H](C)C4CC4)c3n2Cc2ccc(F)c(C(F)(F)F)c2)c1

nearest known ligand 0.78

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
MDM2 Q00987 20/20 0.78

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15921798 1.00 MDM2 (0.78) MDM2
SCHEMBL17313959 0.89 MDM2 (0.75) MDM2
SCHEMBL15921807 0.89 MDM2 (0.75) MDM2
SCHEMBL20105413 0.88 MDM2 (1.00) MDM2
SCHEMBL15930810 0.88 MDM2 (1.00) MDM2
SCHEMBL15921491 0.87 MDM2 (0.86) MDM2
SCHEMBL17314330 0.87 MDM2 (0.86) MDM2
SCHEMBL15921799 0.85 MDM2 (0.58) MDM2
SCHEMBL15922124 0.82 MDM2 (0.55) MDM2
SCHEMBL15930815 0.82 MDM2 (0.89) MDM2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2951180-B1 2,6,7,8 SUBSTITUTED PURINES AS HDM2 INHIBITORS MERCK SHARP & DOHME (US) 2018-05-02 EP disclosed
US-9540377-B2 2,6,7,8 substituted purines as HDM2 inhibitors MERCK SHARP & DOHME CORP. (US) 2017-01-10 US disclosed
US-20150353553-A1 2,6,7,8 SUBSTITUTED PURINES AS HDM2 INHIBITORS MERCK SHARP & DOHME CORP. (US) 2015-12-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150353553-A1 2,6,7,8 SUBSTITUTED PURINES AS HDM2 INHIBITORS DDX21, DPYD, NSUN2 MDM2 55/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.